lung adenocarcinoma: patient selection with ramucirumab vs nintedanib
Published 7 years ago • 370 plays • Length 6:45Download video MP4
Download video MP3
Similar videos
-
6:11
patient selection for ramucirumab in nsclc
-
4:42
practical considerations with nintedanib in lung adenocarcinoma
-
3:25
use of ramucirumab for patients with squamous or nonsquamous lung cancer
-
3:01
nintedanib in lung adenocarcinoma: managing toxicities
-
6:18
treating nsclc with ramucirumab: the revel trial
-
2:48
ramucirumab in relapsed/refractory nsclc
-
6:02
ramucirumab in nsclc
-
6:41
relay: erlotinib with ramucirumab for egfr nsclc
-
3:55
the future of non-driver lung adenocarcinoma
-
8:36
case study: mutation-negative patient with lung adenocarcinoma
-
4:16
ramucirumab data for lung cancer
-
1:55
dr. heather wakelee discusses nintedanib plus chemotherapy in nsclc
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
1:46
dr. martin reck on docetaxel/ramucirumab in nsclc
-
5:07
differentiating among anti-vegf therapies in lung adenocarcinoma
-
6:44
ramucirumab in squamous non-small cell lung cancer
-
5:29
mechanisms of anti-angiogenic therapy in lung cancer
-
4:05
sequencing therapies in advanced lung adenocarcinoma
-
4:08
ramucirumab approval expanded, breakthrough designation for crizotinib, and more